louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02876926: Evaluating a Real-Time, Remote Monitoring System for Home-Based HIV Testing
Official title: Exploring Use of a Real-time, Remote Monitoring and Follow-up System for Home-based, HIV Self-testing Among High-risk Men Who Have Sex With Men (MSM)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV
Keywords: HIV testing
Self-testing
Counseling
Referral
Lead sponsor: Brown University
Sponsor class: OTHER
First posted: 2016-08-24
Enrollment: 65
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This study explores whether offering follow-up counseling and referral over the phone after using a home-based HIV test increases rates of ever and repeat testing, compared with home-based testing with no follow-up (HBST alone) or mailing reminders for clinic-based testing.


Eligibility criteria: Inclusion Criteria:

* Sex with a partner met online in the past year
* Anal sex (either insertive or receptive) with a casual male partner in the past 6 months without using condoms or pre-exposure prophylaxis
* Own a smartphone (iOS or Android) with a service contract and data plan
* Have a stable address where mail can be received
* Speak English fluently

Exclusion Criteria:

* Having tested for HIV in the last year

Primary outcomes:
measure: Number of Participants Who Received HIV Testing
timeFrame: Up to 28 weeks
measure: Number of Participants Who Reported Having Been Referred for Pre-exposure Prophylaxis
timeFrame: Up to 28 weeks
measure: Number of Participants Who Reported Having Actually Received a Prescription for Pre-exposure Prophylaxis
timeFrame: Up to 28 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Providence
country: United States
facility: Brown University School of Public Health
state: Rhode Island
Study officials:
References:
Clinical trial NCT06754826: Learning Diagnostic Reasoning Through AI
Official title: Effectiveness of AI-Generated Questions and Feedback in Learning Diagnostic Reasoning: An Experimental Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Artificial Intelligence (AI)
Clinical Reasoning
Medical Education
Feedback
Keywords: artificial intelligence
diagnostic reasoning
clinical reasoning
medical education
feedback
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2025-01-01
Enrollment: 71
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This experiment aims to determine the effect of AI-generated questions and feedback on diagnostic reasoning in preclinical medical students.

Main Research Question:

What is the effect of AI-generated questions and feedback on diagnostic reasoning skills in preclinical medical students?

Detailed description: This study involves a two groups:

1. Intervention Group: Medical students will receive AI-generated questions and feedback related to five abdominal pain diagnoses.
2. Control Group: Medical students will not receive any intervention. Participants in the intervention group will undergo structured learning sessions consisted of AI-generated questions and feedback as a spaced repetition. Control group will not attend these sessions; they only receive their usual medical training.

The diagnostic reasoning performance will be assessed using a video-based Objective Structured Clinical Examination: OSVE (Objective Structured Video Examination) where videos of "patient-doctor encounters are shown to students and questions related to the video clip are asked. Written answers are marked in a standardised manner."

Eligibility criteria: Inclusion Criteria:

Medical students in Gazi University Faculty of Medicine

Exclusion Criteria:

Medical students outside Gazi University Faculty of Medicine

Primary outcomes:
measure: Diagnostic Reasoning Performance
timeFrame: up to 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gazi University Faculty of Medicine
Study officials:
References:
Clinical trial NCT05838365: Immediate Versus Delayed Loading of Single Posterior Zirconia Implants
Official title: Immediate Versus Delayed Loading of Single Posterior Zirconia Implants: A Multicenter Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Dental Implant Failed
Peri-implant Mucositis
Peri-Implantitis
Lead sponsor: University of Milan
Sponsor class: OTHER
First posted: 2023-05-01
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main aim of the present study is to investigate implant success rate after 5 years of function of immediate (Test group; within 7 days of implant placement) versus delayed (Control group; 8 weeks after implant placement) loading of two-pieces zirconia implant, placed in pristine bone without bone regeneration. Implant success rate will be defined according to Buser's criteria. Secondary endpoints: Marginal bone level (MBL) evaluation by means of standardized radiographs; Clinical evaluation of biological (e.g. Plaque Index, PI; Probing Pocket Depth, PPD, Bleeding on Probing, BOP; suppuration upon probing/palpation) and prosthetic/technical complications; Clinical evaluation of soft tissue width, keratinized tissue, marginal and interproximal soft tissue recession; Patient reported outcome measures (PROMs) by questionnaire administration:


Eligibility criteria: Inclusion Criteria:

* Sistemically healthy patients
* partial edentulism
* premolar position
* molar position
* Bone width and height at least 6 and 10mm, respectively.
* Keratinized tissue, at least 1 mm at implant site
* Full understanding of the proposed surgical treatments and the protocol schedule
* Full comprehension and availability to sign the informed consent form

Exclusion Criteria:

* Heavy smokers (\>10 cigarettes a day)
* Serious kidney or liver diseases
* Uncontrolled diabetes
* Bisphosphonates intake
* History of radiotherapy of the head and neck
* Current antiblastic chemotherapy
* Congenital (primary) or acquired (secondary) immunodeficiency
* Pregnant women
* Connective tissue disorders

Local exclusion criteria:

* untreated stage III/IV periodontitis
* Autoimmune diseases
* oral parafunctions

Primary outcomes:
measure: Implant success rate according to Buser's criteria
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Milano
country: Italy
facility: San Paolo Hospital
Study officials:
References:
Clinical trial NCT03341065: Comparisons of Two Types of Robot Assisted Gait Training
Official title: Comparisons of Two Types of Robot Assisted Gait Training: Exoskeleton Type Robot vs. End-effector Type Robot: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Stroke
Robot Assisted Gait Training
Lead sponsor: National Rehabilitation Center, Seoul, Korea
Sponsor class: OTHER_GOV
First posted: 2017-11-14
Enrollment: 20
Sex: ALL
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparisons of Two Types of Robot Assisted Gait Training: Exoskeleton Type Robot vs. End-effector Type Robot: Randomized Controlled Trial


Eligibility criteria: Inclusion Criteria:

* Hemiplegic patients secondary to first cerebrovascular accidents
* Ankle dorsiflexor strength: medical research council scale 2 or 3
* Functional ambulation category score 3

Exclusion Criteria:

* History of surgery of affected lower limb
* Fracture of affected lower limb

Primary outcomes:
measure: Change of Range of motion of ankle joint at 4 weeks
timeFrame: 4 weeks from baseline
Secondary outcomes:
measure: Trunk impairment scale
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline
measure: Berg Balance Scale
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline
measure: 10m walk test
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline
measure: Fugl-Meyer Assessment
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline
measure: Korean version of Falls efficacy scale
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline
measure: Range of motion of hip joint
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline
measure: Range of motion of knee joint
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline
measure: Range of motion of ankle joint
timeFrame: Baseline, 8 weeks from baseline
measure: Electromyography of lower extremities
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline
measure: Plantar pressure
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline
measure: Step length, time
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline
measure: Functional Ambulation Category
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: National Rehabilitation Center
Study officials:
affiliation: National Rehabilitation Center
name: Joon-Ho Shin, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01329965: Safety and Feasibility of an Endotoxemia Model
Official title: Safety and Feasibility of an Endotoxemia Model: Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cardiovascular Disease
Inflammation
Keywords: Cardiovascular disease
Inflammation
LPS
Endotoxin
Lead sponsor: Penn State University
Sponsor class: OTHER
Collaborators: name: United States Department of Agriculture (USDA)
First posted: 2011-04-06
Enrollment: 6
Sex: ALL
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to establish the safety and feasibility of low dose LPS administration to a small subset of humans in preparation for a larger USDA funded study examining what is the lowest effective dose of EPA + DHA (300, 600, 900 and 1,800 mg/day delivered as fish oil supplements) that significantly attenuates the inflammatory response the investigators wish to examine the effects of an endotoxemia model for inducing inflammation. Based on previous research, low dose LPS administration affects metabolism in humans with only minimal clinical effects (such as "flu" like illness). Therefore, each of the six subjects included in this small pilot study will receive a low dose of LPS and placebo in order to learn more about the metabolic changes that occur during administration and inflammation. The investigators hypothesis that LPS administration will elicit only minimal clinical effects (such as "flu" like illness) when compared to placebo (saline--water with the same amount of salt as in your blood).


Eligibility criteria: Inclusion Criteria:

* Healthy men and non-pregnant/lactating women between the ages of 20 and 35 years old
* BMI \> 19.9 and \< 30.0
* Able to give written informed consent and willing to comply with all study- related procedures

Exclusion Criteria:

* Previous history of heart disease or diabetes
* Renal Insufficiency
* Chronic anti-inflammatory use
* Systolic blood pressure \< 90
* Individuals currently using tobacco products or have done so in the previous 30 days
* Individuals taking Omega-3 fatty acid supplements or their usual intake of fish is greater than 3-4 servings per month

Primary outcomes:
measure: Change in Inflammatory Markers
timeFrame: Baseline (before LPS administration), 1, 2, 3, 4, 6, 12, 24 hrs post LPS administration; 2, 3 and 5 days post LPS administration
Secondary outcomes:
measure: Change in Lipid Mediators
timeFrame: 1, 2, 3 and 5 days post LPS administration
Other outcomes:
Locations:
city: University Park
country: United States
facility: Penn State University
state: Pennsylvania
Study officials:
affiliation: Penn State University
name: Penny M Kris-Etherton, PhD, RD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00366665: Comparison of the Performance of the Infiniti Vision and the Series 20000 Legacy Phacoemulsification Systems
Official title: Comparison of the Infiniti Vision and the Series 20000 Legacy Systems
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cataract Extraction
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
First posted: 2006-08-21
Enrollment: 30
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the efficiency of the Infiniti vision system and the Series 20000 Legacy System phacoemulsification units during routine cataract extraction.


Eligibility criteria: Inclusion Criteria:

* Cataract
* Eligible for cataract extraction with primary implantation of a posterior chamber IOL
* 2 to 3+ cataract density

Exclusion Criteria:

* Preoperative ocular pathology that can affect visual acuity
* Corneal irregularities such as keratoconus, corneal dystrophy, corneal opacities.
* Previous intraocular or corneal surgery.
* Other ocular surgery at the time of the cataract extraction.
* Surgical Exclusion Criteria:
* Significant intraoperative intraocular bleeding
* Detached Descemet's membrane
* Implantation of the intraocular lens in the anterior chamber or sulcus

Primary outcomes:
measure: Ultrasound time
measure: Amount of fluid used
measure: Post operative visual acuity.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Medical University of South Carolina
name: Kerry D. Solomon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06316765: A Stylet Use May be Beneficial for Elective and Rescue Intubation of Prematurely Born Infants
Official title: A Stylet Use May be Beneficial for Elective and Rescue Intubation of Prematurely Born Infants < 30 Weeks.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neonatology
Keywords: Resuscitation
Extremely premature infant
Intubation
Stylet
Lead sponsor: Charles University, Czech Republic
Sponsor class: OTHER
First posted: 2024-03-18
Enrollment: 70
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All premature infants born at less than 30 weeks gestation between 2016 and 2022 in the General Faculty Hospital in Prague were eligible for evaluation.

Brief summary: Contrary to recent findings suggesting that stylets offer no advantage in general infant intubations, this study focuses on their potential benefits for premature infants undergoing elective or rescue intubation in the delivery room. The goal is to compare the safety and efficiency of intubations with or without a stylet.

Detailed description: Recent studies have found that using a stylet does not offer any benefits during intubation across a diverse infant population. The research, however, specifically targets extremely and very premature infants undergoing elective or rescue intubation in the delivery room. A single-center retrospective observational study was conducted to compare the number of intubation attempts, the duration of intubation until successful, and the rate of associated desaturations exceeding 20%. The outcomes were determined through video recordings and statistical analysis.

Eligibility criteria: Inclusion Criteria:

* intubation in the delivery room

Exclusion Criteria:

* both method used, video record not available

Primary outcomes:
measure: The primary outcome was defined as successful initial intubation attempt.
timeFrame: immediately after procedure
Secondary outcomes:
measure: Secondary outcomes was defined as the duration of intubation courses until successful placement of the endotracheal tube.
timeFrame: immediately after procedure
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03392766: Fiberoptic Bronchoscope of Double Lumen Tube and Single Lumen Tube in Patients With Semi-regid Neck Collar.
Official title: Comparison of Fiberoptic Intubation Between Double Lumen Tube and Single Lumen Tube in Patients With Semi-rigid Neck Collar Immobilization of the Cervical Spine.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intubation;Difficult
Thoracic Diseases
Keywords: fibreoptic intubation
double lumen tube
difficult intubation
Lead sponsor: Ajou University School of Medicine
Sponsor class: OTHER
First posted: 2018-01-08
Enrollment: 80
Sex: ALL
Minimum age (years): 19
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Many intrathoracic procedures demand optimal collapse of the operative lung to facilitate surgical exposure. Single-lung ventilation can be achieved using a double-lumen tube (DLT), a Univent tube, or an independent bronchial blocker. Insertion of a DLT using a direct laryngoscope can be more difficult than that of single-lumen tube (SLT), especially in patients for whom airway difficulty is anticipated. The safest of the proposed methods involves the placement of an SLT with the aid of an fibreoptic bronchoscope (FOB), following which the SLT is replaced with a DLT using an airway exchange technique in these patients. HumanBroncho® (Insung Medical, Seoul, Korea) is a new silicone DLT with a soft, flexible, non-bevelled, wire-reinforced tip. The oval shape, obtuse angle, and short lateral internal diameter of the bronchial lumen and its flexibility may allow for advancement to the trachea over the FOB with as much as ease as a standard SLT. In the present study, the investigators aimed to test the hypothesis that the HumanBroncho® DLT would be non-inferior to a standard SLT with regard to intubation time over an FOB in patients with semi-rigid neck collar simulating difficult airway.


Eligibility criteria: Inclusion Criteria:

* patients undergoing thoracic surgery requiring one lung ventilation. American Society of Anesthesiologist, Physical Status 1,2

Exclusion Criteria:

* abnormality of upper airway gastroesophageal disease risk of aspiration BMI \> 35

Primary outcomes:
measure: intubation time
timeFrame: through study completion, an average of 4 hour
Secondary outcomes:
measure: insertion time
timeFrame: through study completion, an average of 4 hour
measure: railroading time
timeFrame: through study completion, an average of 4 hour
measure: grade of ease of insertion over fibreoptic bronchoscope
timeFrame: through study completion, an average of 4 hour
measure: trauma around the glottis
timeFrame: through study completion, an average of 4 hour
measure: complication at the post-anesthesia care unit
timeFrame: through study completion, an average of 4 hour
Other outcomes:
Locations:
city: Suwon
country: Korea, Republic of
facility: Ajou universiry hospital
state: Gyeonggi-do
Study officials:
affiliation: Ajou unversity hospital
name: Dae Hee Kim, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00397566: A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects
Official title: Randomized, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-707035 in HIV-1 Infected Subjects
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: HIV Infections
Keywords: HIV
Treatment Experienced
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2006-11-09
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical research study is to assess the safety, pharmacokinetics and pharmacodynamics of BMS-707035 in subjects infected with HIV-1


Eligibility criteria: Inclusion Criteria:

* HIV-1-infected subjects with CD4+ lymphocyte count ≥ 200 cells/mm3 and with plasma HIV-1 RNA ≥ 5000 copies/mL who have not been on antiretroviral (ARV) therapy for ≥ 8 weeks or who are naive to ARV, and who are otherwise medically stable as determined by medical history, physical examination, 12 lead electrocardiogram, and clinical laboratory evaluations will be eligible to participate in the study. In addition, subjects must have had no prior exposure to the Integrase Inhibitor class of compounds.
* Female subjects must not be nursing, pregnant, or of childbearing potential

Primary outcomes:
measure: To assess the antiviral activity of selected doses of BMS-707035 administered orally to HIV-1 infected subjects for 10 days.
Secondary outcomes:
measure: Safety and tolerability with 10 days of dosing
measure: Effect on QTc intervals
measure: Effect on CD4+, CD8+, and CD8+CD38+ lymphocyte
measure: Pharmacokinetics of multiple doses of BMS-707035 in HIV-1 infected subjects
measure: Assess relationship of EC90 and exposures of BMS-707035 to the magnitude of change in viral loads
measure: Assess plasma protein binding and intracellular concentration in PBMC for BMS-707035
Other outcomes:
Locations:
Study officials:
References: